A bispecific antibody that inhibits PD-1 and EGFR (anti-PD-1 x anti-EGFR) has been shown to significantly suppress tumor growth and activate antitumor immunity in animal models of various types of cancer [60]. Here, PDCD1 is linked to neoplasm.